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Abstract 
Background: Incretin-based agents, including dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like pep-
tide-1 agonists (GLP-1As), work via GLP-1 receptor for hyperglycemic control directly or indirectly, but have different 
effect on cardiovascular (CV) outcomes. The present study is to evaluate and compare effects of incretin-based agents 
on CV and pancreatic outcomes in patients with type 2 diabetes mellitus (T2DM) and high CV risk.
Methods: Six prospective randomized controlled trials (EXMAINE, SAVOR-TIMI53, TECOS, ELIXA, LEADER and SUS-
TAIN-6), which included three trials for DPP-4Is and three trials for GLP-1As, with 55,248 participants were selected to 
assess the effect of different categories of incretin-based agents on death, CV outcomes (CV mortality, major adverse 
CV events, nonfatal myocardial infarction, nonfatal stroke, heart failure hospitalization), pancreatic events (acute pan-
creatitis and pancreatic cancer) as well as on hypoglycemia.
Results: When we evaluated the combined effect of six trials, the results suggested that incretin-based treatment 
had no significant effect on overall risks of CV and pancreatic outcomes compared with placebo. However, GLP-1As 
reduced all-cause death (RR = 0.90, 95% CI 0.82–0.98) and CV mortality (RR = 0.84, 95% CI 0.73–0.97), whereas DPP-4Is 
had no significant effect on CV outcomes but elevated the risk for acute pancreatitis (OR = 1.76, 95% CI 1.14–2.72) 
and hypoglycemia (both any and severe hypoglycemia), while GLP-1As lowered the risk of severe hypoglycemia.
Conclusions: GLP-1As decreased risks of all-cause and CV mortality and severe hypoglycemia, whereas DPP-4Is had 
no effect on CV outcomes but increased risks in acute pancreatitis and hypoglycemia.
Keywords: Glucagon-like peptide-1 agonists, Dipeptidyl peptidase-4 inhibitors, Type 2 diabetes mellitus, 
Cardiovascular outcomes, Acute pancreatitis
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Background
The risk of cardiovascular (CV) events is two to four 
times higher in patients with type 2 diabetes melli-
tus (T2DM) compared with those without diabetes 
[1–4] and also a major cause of death for these patients 
[5], indicating that efficient glucose management may 
improve CV outcomes. However, some antidiabetic drugs 
such as thiazolidinediones had been reported to increase 
incidence of heart failure [6–8]. Motivated by concerns 
regarding the potential association between antidiabetic 
agents and adverse CV outcomes, the Food and Drug 
Administration issued a guidance that any new antidia-
betic agent was required to comprehensively evaluate its 
CV safety [9]. Notably, corresponding CV outcome trial 
should include subjects at high CV risk [10], which pre-
sent a patient population more vulnerable, to obtain an 
Open Access
Cardiovascular Diabetology
*Correspondence:  xfyu188@163.com 
Division of Endocrinology, Department of Internal Medicine, Tongji 
Hospital, Tongji Medical College, Huazhong University of Science 
and Technology, 1095 Jiefang Avenue, Wuhan 430030, Hubei Province, 
People’s Republic of China
Page 2 of 10Zhang et al. Cardiovasc Diabetol  (2017) 16:31 
event rate high enough to ascertain the CV safety of the 
agent [11].
Incretin-based agents include both dipeptidyl pepti-
dase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 
agonists (GLP-1As). DPP-4Is prevent the degradation 
of endogenous glucagon-like peptide-1 (GLP-1) and 
GLP-1As provide supra-physiological concentrations 
of “GLP-1 mimetics”. Both of them exert their effect by 
activating GLP-1 receptor for glucose control in patients 
with T2DM. However, DPP-4Is and GLP-1As are two dif-
ferent classes of molecules and they have different effects 
on CV outcomes [12] as well as corresponding param-
eters such as body weight [13]. Studies focused on CV 
safety are available now and results indicate that incre-
tin-based agents have no adverse effect on CV outcomes 
except saxagliptin increasing risk of heart failure hospi-
talization [14] and certain GLP-1As have shown CV pro-
tective effect [15, 16]. Furthermore, it has been reported 
that incretin-based agents such as exenatide or sitaglip-
tin may increase the risk of pancreatitis [17]. Therefore, 
a comprehensive assessment of incretin-based agents in 
combination and separately is important.
Previous meta-analysis and systematic reviews ana-
lyzed safety of incretin-based agents for CV outcomes 
but most of previous meta-analyses were performed 
based on studies with different follow-up durations, 
diverse populations of T2DM and most importantly, 
primary endpoints of these studies did not focus on CV 
events [18–28]. Recently, only one meta-analysis focused 
on DPP-4I studies with primary endpoints for CV out-
comes [29], but missing important studies assessing 
newer GLP-1As. To update and clarify new accumulated 
evidence for CV and pancreatic safety of incretin-based 
agents, we conducted a meta-analysis using all available 
published trials for CV outcomes in patients with T2DM 




Eligible English-language randomized controlled trials 
(up to October 2016) were identified through literature 
search with medical subject heading terms and key-
words related to “randomized controlled trials”, “DPP-
4Is” (“alogliptin”, “dutogliptin”, “linagliptin”, “omarigliptin”, 
“saxagliptin”, “sitagliptin”, “vildagliptin”) and “GLP-1As” 
(“albiglutide”, “dulaglutide”, “exenatide”, “liraglutide”, 
“lixisenatide”, “semaglutide”, “taspoglutide”) in Medline, 
Embase, Cochrane library and ClinicalTrials.gov. In addi-
tion, a search of the reference lists of eligible trials and 
conference abstracts were also conducted to supplement 
eligible studies.
Study selection
Studies meeting the following predefined criteria were 
included in our analysis: [1] phase 3 and phase 4 tri-
als; [2] compare incretin-based agents with placebo in 
patients with T2DM and increased risk for CV diseases; 
[3] follow-up for a median time of at least 52  weeks; 
[4] enroll at least 1000 participants; [5] report CV and 
other safety data for each treatment group separately. To 
focus on large, high quality randomized controlled tri-
als, we excluded trials enrolling fewer than 1000 patients, 
or those failed to randomize properly, or not double-
blinded. Head-to-head studies, early reports of the same 
studies and studies conducted in low CV risk patients 
were also excluded (Fig. 1).
Six randomized controlled trials met our selection cri-
teria and were included in this meta-analysis: EXamina-
tion of cArdiovascular outcomes with alogliptIN versus 
standard of carE in patients with type 2 diabetes mellitus 
and acute coronary syndrome (EXAMINE) [30, 31], the 
Fig. 1 Study flow chart. T2DM type 2 diabetes mellitus, CV cardiovas-
cular
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Saxagliptin Assessment of Vascular Outcomes Recorded 
in patients with diabetes mellitus-Thrombolysis in Myo-
cardial Infarction 53 (SAVOR-TIMI53) [14] and Trial 
Evaluating Cardiovascular Outcomes with Sitaglip-
tin (TECOS) [32] tested DPP-4Is, while Lixisenatide in 
Patients with Type 2 Diabetes and Acute Coronary Syn-
drome (ELIXA) [33], Liraglutide Effect and Action in 
Diabetes: Evaluation of CV Outcome Results (LEADER) 
[15] and Semaglutide and Cardiovascular Outcomes in 
Patients with Type 2 Diabetes (SUSTAIN-6) [16] tested 
GLP-1As (Table 1).
Data extraction
We abstracted the following data from each study: study 
characteristics (title of specific article, first author, sam-
ple size for each group, countries involved, number of 
study sites, year of publication, length of follow-up and 
study design), baseline characteristics of participants 
(age, sex, race, body mass index (BMI), duration of dia-
betes, hemoglobin A1c (HbA1c), medications commonly 
administrated across groups at baseline (beyond incretin-
based agents) and other major risk factors, interventions 
(details of incretin-based therapies, such as names of spe-
cific agents, dose) and post-intervention changes (includ-
ing changes of mean concentrations of HbA1c, body 
weight, systolic pressure and diastolic pressure) (Table 1) 
and outcomes (absolute numbers of outcomes for both 
treatment arms, Figs. 2, 3, 4) were presented.  
CV outcomes abstracted were as follows: all-cause mor-
tality, CV mortality, major adverse CV events (MACE), 
nonfatal myocardial infarction (MI), nonfatal stroke and 
heart failure hospitalization. In addition, the incidences 
of pancreatic outcomes (acute pancreatitis and pancreatic 
cancer) and hypoglycemia (any hypoglycemia and severe 
hypoglycemia) were recorded. As definitions of these end-
points varied between studies, each endpoint was defined 
for each study in Additional file 1: Table S1.
Relevant data for analysis were extracted independently 
by two authors (ZZ and XC) using a standardized format. 
Discrepancies were resolved by consensus or by a senior 
investigator (XY).
Data synthesis and analysis
Information for baseline characteristics were obtained 
with means (standard deviations) or rates from eligible 
studies. For most outcomes of interest, RRs (risk ratios) 
were pooled using both fixed- and random-effects mod-
els. Similarly, both the Cochran’s Q statistic and the I2 
measure were used to assess the heterogeneity across 
studies. We considered p value less than 0.10 in Q sta-
tistic and I2 values of over 50% represented significant 
heterogeneity [34]. Therefore, evidence of heterogene-
ity between trials was shown for several outcomes (any 
hypoglycemia, severe hypoglycemia and pancreatic can-
cer), although findings from fixed-effects models were 
comparable to those from random-effects models (Addi-
tional file  1: Table S2). Additionally, the exact incretin-
based therapies, lengths of follow-ups, diabetes durations 
of participants and achieved HbA1c varied between trials. 
Thus, only results from random-effects models which 
assume these underlying impacts were present. For acute 
pancreatitis and pancreatic cancer, outcome data were 
pooled using Peto’s methods considering the relatively 
low event rates [35]. Subgroup analyses were performed 
for different types of incretin-based agents (DPP-4Is or 
GLP-1As) and our analyses were conducted on an inten-
tion-to-treat basis.
Sensitivity analysis was carried out when required. 
Alternative effect measures (RRs versus odds ratios, 
ORs) and pooling methods (Mantel-Hanszel versus Peto 
method) were tried to ensure the reliability of our results. 
Potential publication bias was visually evaluated with 
funnel plots. Furthermore, we formally assessed potential 
publication bias by both Begg’s [36] and Egger’s tests [37].
All tests were two-sided and p  <  0.05 was considered 
significant. Analyses were done with STATA (Release 
12.0; Stata Corporation, College Station, TX, USA).
Results
As we showed in Table  1, a total of 55,248 participants 
were included and the average duration of follow-up 
(weighted by study size) was 2.6  years (median par-
ticipant follow-up ranged from 1.5  years for EXAM-
INE to 3.8  years for LEADER). Participants were aged 
60.3 to 66.0 years, with more than half were male. More-
over, most subjects included in our study were over-
weight or obese (BMI ranging from 28.7 to 32.8 kg/m2). 
BMI of participants were 28.7 to 31.1  kg/m2 in DPP-4I 
trials and 30.2  to  32.8  kg/m2 in GLP-1A trials. Similar 
lipid profile, blood pressure and co-administrated agents 
were observed among the trials. However, compared with 
participants in other trials, EXAMINE participants had 
shorter diabetes durations and lower BMI, whilst higher 
HbA1c were recorded in participants of LEADER and 
SUSTAIN-6. All these trials showed lower post-inter-
vention HbA1c concentrations in participants treated 
with incretin-based agents than those with placebo, with 
mean differences ranging from −1.0 to −0.1%. The body 
weight were declined in all GLP-1A trials.
No overall effects of incretin-based agents on all-cause 
mortality (RR = 0.97, 95% CI 0.89–1.06) or CV mortal-
ity (RR =  0.96, 95% CI 0.86–1.07) were found and this 
was mainly due to the fact that pooling data from DPP-
4I trials EXAMINE, SAVOR-TIMI53 and TECOS caused 
no change for the two outcomes. However, results from 
GLP-1A trials showed protective effects on both all-cause 
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(RR  =  0.90, 95% CI 0.82–0.98) and CV (RR  =  0.84, 
95% CI 0.73–0.97) mortality (Fig.  2a, b). No impacts of 
incretin-based agents were identified in both overall and 
subgroup analyses for the risk of MACE, nonfatal MI, 
nonfatal stroke or heart failure hospitalization (Fig.  2c–
e). It is important to note that GLP-1As reduced all-
cause and CV mortality were mainly caused by LEADER 
study, which accounted for 56.21 and 56.76% of overall 
results of GLP-1A trials for all-cause and CV mortality, 
respectively.
Incretin-based agents did not significantly affect acute 
pancreatitis (OR  =  1.16, 95% CI 0.85–1.59, Fig.  3a) 
and pancreatic cancer (OR  =  0.71, 95% CI 0.45–1.11, 
Fig.  3b). Our further analyses by comparing different 
classes of incretin-based agents suggested that GLP-
1As were not associated with excess risks of either acute 
pancreatitis (OR =  0.75, 95% CI 0.47–1.17) or pancre-
atic cancer (OR  =  0.94, 95% CI 0.49–1.83). However, 
DPP-4Is significantly elevated the risk of acute pancrea-
titis (OR =  1.76, 95% CI 1.14–2.72) and had no effect 
on the risk of pancreatic cancer (OR  =  0.55, 95% CI 
0.29–1.02).
Although pooling findings from the six trials (EXAM-
INE, SAVOR-TIMI53, ELIXA, LEADER and SUSTAIN-6) 
showed incretin-based agents were not associated with 
any or severe hypoglycemia (RR = 1.05, 95% CI 0.96–1.15 
for any hypoglycemia, RR =  0.97, 95% CI 0.74–1.26 for 
severe hypoglycemia, Fig. 4), DPP-4Is increased the risk 
Fig. 2 Probability of events of mortality and CV outcomes with incretin-based agents versus placebo. Effect of incretin-based agents on all-
cause mortality (a), CV mortality (b), MACE (c), nonfatal MI (d), nonfatal stroke (e) and heart failure hospitalization (f) was analyzed individually. CI 
confidence interval, DPP-4I dipeptidyl peptidase-4 inhibitor, GLP-1A glucagon-like peptide-1 agonist, CV cardiovascular, MACE major cardiovascular 
events, MI myocardial infarction
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of both types of hyperglycemia and GLP-1As decreased 
risk for severe hypoglycemia (Fig. 4b).
In sensitivity analyses, the effect estimate was con-
sistent when primary meta-analysis was repeated using 
alternative effect measures, pooling methods and statisti-
cal models. Visual inspection of funnel plots asymmetry 
revealed no evidence of substantial publication bias for 
any outcome we studied, which was further confirmed by 
Begg’s and Egger’s tests (Additional file 1: Table S3).
Discussion
Incretin-based agents as an innovative class of hypogly-
cemic medications have several advantages over existing 
drugs, including glucose-dependent insulin release and 
weight reduction for GLP-1As or no weight gain for DPP-
4Is [38]. Our present meta-analysis included data from 
six large CV outcome trials to compare the CV and pan-
creatic effects of incretin-based agents with placebo in 
patients with T2DM and high CV risk. The main findings 
of the present analysis showed that GLP-1As reduced the 
risks of all-cause and CV mortality and severe hypogly-
cemia. DPP-4Is had no adverse effect on all-cause death 
and CV mortality. However, they increased risks of acute 
pancreatitis and hypoglycemia.
The combined analysis from present data showed that 
incretin-based agents had no adverse effect on CV safety, 
which was similar to a recent study conducted in patients 
with T2DM and chronic kidney disease [39]. Notably, 
GLP-1As decreased both all-cause and CV mortality in 
the present study. Previous studies showed that GLP-
1As had inconsistent effect on CV safety [26, 40–44]. 
More importantly, several studies showed that GLP-1As 
mainly improved certain CV risk factors such as systolic 
blood pressure, low density lipoprotein-cholesterol, total 
cholesterol, triglycerides [45], body weight and waist cir-
cumference [46], or ameliorate the CV events compared 
with active agent such as insulin [47] and sulphonylu-
reas [48]. At the present time, only three high-quality 
CV outcome studies of GLP-1As were carried out and 
included in our analysis. Among them, two showed CV 
Fig. 3 Probability of events of pancreatic outcomes with incretin-based agents versus placebo. Effect of incretin-based agents on acute pancrea-
titis (a) and pancreatic cancer (b) was analyzed individually. CI confidential interval, DPP-4I dipeptidyl peptidase-4 inhibitor, GLP-1A glucagon-like 
peptide-1 agonist
Fig. 4 Probability of events of hypoglycemia with incretin-based agents versus placebo. Effect of incretin-based agents on any (a) and severe (b) 
hypoglycemia was analyzed individually. CI confidence interval, DPP-4I dipeptidyl peptidase-4 inhibitor, GLP-1A glucagon-like peptide-1 agonist
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protective effect. The possible mechanisms underlying 
may be associated with reduction of body weight and 
blood pressure and lowering the risk for hypoglycemia. 
First, studies showed that all-cause mortality was signifi-
cantly increased with BMI in patients with T2DM, espe-
cially when BMI ≥30 kg/m2 [49], and decreasing systolic 
blood pressure was associated with decline of all-cause 
death and CV mortality [50, 51]. As shown in the present 
studies with GLP-1As, all individuals included had aver-
age BMI above 30 kg/m2 and reduction of all-cause and 
CV mortalities was observed as decreased body weight 
and blood pressure were detected in all participants. For 
instance, body weight reduction was 2.9 or 4.3  kg and 
systolic pressure reduction was 1.3 or 2.6 mmHg in SUS-
TAIN-6 trial, 2.3 kg and 1.2 mmHg in LEADER trial and 
0.7 kg in ELIXA study. Second, GLP-1As reduced severe 
hypoglycemia which usually associate with increasing of 
CV events [52, 53], and this may also account for their 
CV benefits.
In contrast with GLP-1As, DPP-4Is had no obvious 
effect on all-cause and CV mortality in patients with 
T2DM and high CV risk. Actually, recent data on DPP-
4Is failed to show improvements with CV functions 
apart from T2DM patients free of a history of appar-
ent CV diseases [54–56]. It is worthy to note that DPP-
4Is elevated endogenous GLP-1 to physiological levels 
(10  to  25  pmol/l), whereas GLP-1As reached higher 
pharmacological concentrations (for example, free active 
liraglutide levels were in the range 60 to 90 pmol/l) and 
also increased endogenous GLP-1 [12, 57]. This may 
explain that GLP-1As have stronger effect on glycemic 
control and exert their CV protective effect. At the same 
time, the fact that DPP-4Is increased hypoglycemia may 
account for their non-beneficial effect on CV outcomes 
as GLP-1As did although endogenous GLP-1 levels were 
elevated.
When both classes of incretin-based treatment were 
combined, no significant effects on acute pancreatitis 
and pancreatic cancer were identified. These results were 
in line with a large population-based cohort study pub-
lished very recently [58]. However, a refined picture was 
provided in our study. We found only DPP-4Is increased 
acute pancreatitis and there is no clear mechanism 
accounting for the different effects of the two types of 
incretin-based agents on this outcome. Notably, a recent 
study demonstrated that the patients with pancreatitis 
had reduced secretion of glucagon which might account 
for hypoglycemia [59]. The fact that DPP-4Is increased 
risk of hypoglycemia may suggest that these individuals 
already had certain degree of pancreas impairment, or 
DPP-4I molecular itself may increase risk for hypoglyce-
mia and acute pancreatitis directly or by causing a pre-
disposing factor for these adverse events, since DPP-4Is 
increased both hypoglycemia and pancreatitis as showed 
in our study. A head-to-head comparison of GLP-1A and 
DPP-4I for their effect on pancreatic safety may be help-
ful to clarify this issue.
The strength of our analysis is that we update the accu-
mulated evidence to evaluate CV and pancreatic safety 
profile of incretin-based agents in T2DM patients at 
risk for CV diseases. More than 50,000 participants in 
six large and high-quality randomized controlled trials 
were included for our meta-analysis, and this ensures a 
strong power to detect not only their primary outcomes 
but small and important effects of incretin-based agents 
in patients.
On the other side, we must acknowledge the limita-
tions of our meta-analysis. First, our meta-analysis were 
performed on summary data, thus leading to a relatively 
poor accuracy of assessment compared with individual-
level analyses. Second, although our study showed that 
GLP-1As decreased all-cause death and CV mortal-
ity, the relatively short-term exposure of incretin-based 
agent in the studies we included may not be enough to 
show other potential events related to CV outcomes [38], 
especially for the DPP-4Is [60–68]. Third, randomized 
controlled trials included in our study may not reflect 
what happens in real world. However, results from a 
recent study showed the improvement in glycemia, which 
may affect CV and pancreatic outcomes, was the same in 
randomized controlled trials and the observational trial 
for vildagliptin [69].
Conclusions
In conclusion, our meta-analysis reassures the CV safety 
of incretin-based agents among patients with T2DM and 
pre-existing CV risk. The impacts of these agents on CV 
and pancreatic outcomes seem to be class-specific, with 
favorable impacts on all-cause and CV mortality for GLP-
1As and a detrimental one on acute pancreatitis for DPP-
4Is. Moreover, hypoglycemia, as an important adverse 
event in the current analysis, may be related to the risk 
profile of CV and pancreatic outcomes. In the absence of 
long-term head-to-head trials, our analysis may provide 
insights into the comparative safety profile of DPP-4Is 
relative to GLP-1As. From view of this respect, GLP-1As 
may be prioritized over DPP-4Is in T2DM patients at CV 
risk.
Additional file
Additional file 1: Table S1. Shows definitions of T2DM, established CV 
risk and other endpoints for each trial. Table S2. Shows overall estimates 
of the effects of incretin-based agents on several outcomes using fixed- 
and random-effects models. Table S3. Shows evaluation of heterogeneity 
and publication bias for studies included in the meta-analysis.
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